Compare NUVL & CUBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | CUBE |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.8B |
| IPO Year | 2021 | 2004 |
| Metric | NUVL | CUBE |
|---|---|---|
| Price | $123.60 | $39.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $134.75 | $44.00 |
| AVG Volume (30 Days) | ★ 4.2M | 1.9M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $1,123,110,000.00 |
| Revenue This Year | N/A | $0.66 |
| Revenue Next Year | $1,239.49 | $2.82 |
| P/E Ratio | ★ N/A | $110.53 |
| Revenue Growth | N/A | ★ 5.33 |
| 52 Week Low | $71.14 | $35.09 |
| 52 Week High | $123.69 | $43.63 |
| Indicator | NUVL | CUBE |
|---|---|---|
| Relative Strength Index (RSI) | 66.56 | 46.06 |
| Support Level | $98.56 | $39.91 |
| Resistance Level | $123.62 | $40.91 |
| Average True Range (ATR) | 0.21 | 0.77 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 82.41 | 24.56 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.